Ascentage Pharma Group International
ASPHFOTCHealthcare● Active
$4.53
$-0.17(-3.51%)
Market Cap$1.7B
P/E Ratio—
52W High$10.65
52W Low$4.53
Ascentage Pharma Group International (ASPHF) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ASPHF · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($1.24B) | ($0.40B) | ($0.93B) | ($0.88B) | ($0.78B) |
| Depreciation & Amort. | $0.09B | $0.09B | $0.09B | $0.06B | $0.03B |
| Stock-Based Comp. | $0.02B | $0.02B | $0.03B | $0.02B | $0.05B |
| Change in Working Capital | ($0.14B) | $0.11B | ($0.01B) | ($0.01B) | ($0.06B) |
| Net Cash from Operations | ($1.17B) | ($0.11B) | ($0.73B) | ($0.65B) | ($0.60B) |
| Investing Activities | |||||
| Capital Expenditure | ($0.03B) | ($0.02B) | ($0.06B) | ($0.20B) | ($0.44B) |
| Purchases of Investments | ($0.93B) | $0.00B | $0.00B | ($0.13B) | ($1.78B) |
| Sales of Investments | $0.00B | $0.00B | $0.00B | $0.15B | $1.79B |
| Net Cash from Investing | ($1.00B) | ($0.36B) | $0.02B | ($0.38B) | ($0.47B) |
| Financing Activities | |||||
| Common Stock Repurchased | ($0.01B) | $0.00B | ($0.01B) | ($0.03B) | ($0.03B) |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $0.31B | ($0.15B) | ($0.01B) | $0.71B | $0.55B |
| Net Cash from Financing | $2.54B | $0.31B | $0.37B | $0.62B | $1.78B |
| Free Cash Flow | |||||
| Free Cash Flow | ($1.20B) | ($0.14B) | ($0.78B) | ($0.86B) | ($1.04B) |
| FCF Margin %(computed) | -214.86% | -13.83% | -352.69% | -408.75% | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · CNY · B
Explore more Ascentage Pharma Group International data
About Ascentage Pharma Group International (ASPHF) Cash Flow Statement
Ascentage Pharma Group International generated operating cash flow of ($1.17B) and free cash flow of ($1.20B) for 2025 — a FCF margin of -214.86%. Capital expenditure was ($0.03B).
Frequently asked questions
ASPHF · 4 questionsAscentage Pharma Group International generated free cash flow of ($1.20B) for 2025, down 785.9% year-over-year.
ASPHF free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10